1.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181132, NCT00706706
|
|
2.
|
Phase: Phase IV
Type: Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 13102, NCT00771147
|
|
3.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UMCNONCO200801, NCT00777504
|
|
4.
|
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181181, NCT00836745
|
|
5.
|
Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181185, NCT00873210
|
|
6.
|
Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: P070104, NCT00930345
|
|
7.
|
Phase: Phase IV
Type: Natural history/Epidemiology
Status: Active
Age: Not specified
Sponsor: Pharmaceutical / Industry
Protocol IDs: 14792, NX0910KR, NCT01012011
|
|
8.
|
Phase: Phase IV
Type: Health services research, Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181189, NCT01033981
|
|
9.
|
Phase: Phase IV
Type: Behavioral study, Prevention
Status: Active
Age: 18 and over
Sponsor: Other, Pharmaceutical / Industry
Protocol IDs: 07-0585-AE, Protocol# in Pfizer: GA30517W, NCT00937508
|
|
10.
|
Phase: Phase IV
Type: Behavioral study, Prevention
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 005/2008, NCT01015170
|
|
11.
|
Phase: Phase IV
Type: Behavioral study, Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 16 to 65
Sponsor: Other
Protocol IDs: MD-095-PP-05A, NCT00495352
|
|
12.
|
Phase: Phase IV
Type: Behavioral study, Prevention
Status: Active
Age: 16 to 45
Sponsor: Other
Protocol IDs: P50DA016511, NCT00664755
|
|
13.
|
Phase: Phase IV
Type: Behavioral study, Prevention
Status: Active
Age: 18 to 60
Sponsor: Other
Protocol IDs: 2009-P-000444, NCT00907218
|
|
14.
|
Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 120
Sponsor: Other
Protocol IDs: 9359-03, 2003-006, NCT00221728
|
|
15.
|
Phase: Phase III, Phase II
Type: Behavioral study, Prevention
Status: Approved-not yet active
Age: 18 to 75
Sponsor: Other
Protocol IDs: NURA-001-09S, NCT00960375
|
|
16.
|
Phase: Phase III, Phase II
Type: Behavioral study, Prevention
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: NIDA-16427-5, R01-16427-5, DPMC, NCT00132821
|
|
17.
|
Phase: Phase III, Phase II
Type: Behavioral study, Biomarker/Laboratory analysis, Prevention
Status: Active
Age: 18 to 65
Sponsor: NCI, Other
Protocol IDs: 2003-1024, 1R01DA017073, NCT00507728
|
|
18.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181034, NCT00083889
|
|
19.
|
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: ECOG-E2805, E2805, CALGB-E2805, SWOG-E2805, CAN-NCIC-E2805, NCT00326898
|
|
20.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: A6181109, NCT00375674
|
|
21.
|
Phase: Phase III
Type: Health services research
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: SWS-SAKK-95/06, SAKK-95/06, EU-20711, SWS-SAKK-E-MOSAIC, NCT00477919
|
|
22.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: MRC-RE05-SORCE, MRC-RE05-SORCE, EUDRACT ID 2006-006079-19, EU-20734, NCT00492258, SORCE, ISRCTN38934710
|
|
23.
|
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: INSYS-INS-05-001, INS-05-001, NCT00538850, NCT00538850
|
|
24.
|
Phase: Phase III
Type: Supportive care
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: INSYS-INS-06-007, INS-06-007, NCT00538863
|
|
25.
|
Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 3066K1-3311, NCT00631371
|
